

# EMFLAZA (deflazacort)

### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

**Age** 2 years of age or older

**Diagnosis** 

Patient must have the following:

Duchenne muscular dystrophy (DMD)

#### **AND ALL** of the following:

- a. Genetic confirmation of DMD
- b. Serum creatinine kinase activity at least 10 times the upper limit of normal (ULN) prior to initiating treatment
- Inadequate treatment response, intolerance, or contraindication to a 3 month trial of prednisone
- d. Obtain a baseline motor milestone score from **ONE** the following assessments:
  - i. 6-minute walk test (6MWT)
  - North Star Ambulatory Assessment (NSAA)
  - iii. Motor Function Measure (MFM)
- e. NOT given concurrently with live vaccinations
- f. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
- g. If the patient has a history of hepatitis B (HBV) infection Prescriber agrees to monitor for HBV reactivation

### **Prior - Approval Limits**

**Duration** 6 months

## Prior – Approval Renewal Requirements

**Age** 2 years of age or older



## EMFLAZA (deflazacort)

#### **Diagnosis**

Patient must have the following:

Duchenne muscular dystrophy (DMD)

#### **AND ALL** of the following:

- a. Stabilization OR improvement in motor milestone score from baseline from **ONE** the following assessments:
  - i. 6-minute walk test (6MWT)
  - ii. North Star ambulatory assessment (NSAA)
  - iii. Motor Function Measure (MFM)
- b. **NOT** given concurrently with live vaccinations
- c. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
- d. If the patient has a history of hepatitis B (HBV) infection
  - i. Prescriber agrees to monitor for HBV reactivation

## Prior - Approval Renewal Limits

**Duration** 12 months